UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  FORM 10-Q  [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the quarterly period ended September 30, 2009  [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from ___________ to ______________  Commission File Number: 000-53213   SINOCOM PHARMACEUTICAL, INC (Exact name of registrant as specified in its charter)  Nevada26-1188540(State or other jurisdiction of incorporation)(IRS Employer Identification Number)Room 3, 21/F, Far East Consortium Building
121 Des Voeux Road
Central, Hong Kong(Address of principal executive offices)011-852-2159-7863(Registrants telephone number, including area code)  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  [ X ] Yes   [ ] No  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.


|                                                                         |                                
|------------------------------------------------------------------------ | -------------------------------
|Large accelerated filer [ ]                                              | Accelerated filer [ ]          
|Non-accelerated filer [ ]  (Do not check if a smaller reporting company) | Smaller reporting company [ X ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [   ] Yes   [ X ] No  As of September 30, 2009 the Issuer had 71,416,660 shares of common stock issued and outstanding.


PART I-FINANCIAL INFORMATION  ITEM 1. FINANCIAL STATEMENTS.    The consolidated financial statements of Sinocom Pharmaceutical, Inc. (the "Company" or the Registrant), a Nevada corporation, included herein were prepared, without audit, pursuant to rules and regulations of the Securities and Exchange Commission.  Because certain information and notes normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America were condensed or omitted pursuant to such rules and regulations, these financial statements should be read in conjunction with the audited consolidated financial statements of Rolling Rhine Holdings, Ltd., a corporation organized under the laws of the British Virgin Islands, for the fiscal years ended December 31, 2008 and 2007, and notes thereto, included in the Company's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 23, 2009, relating to the closing of a share exchange transaction between the Company and Rolling Rhine Holdings, Ltd., in which Rolling Rhine Holdings, Ltd., and its subsidiaries, China Zhongxi Yao Group Limited,  a Hong Kong corporation, and Anqing Zhongxi Yao, Ltd., a PRC corporation became wholly-owned subsidiaries of the Company, and the Company succeeded to the business operations carried on by Anqing Zhongxi Yao, Ltd..      2         SINOCOM PHARMACEUTICAL, INC CONSOLIDATED FINANCIAL STATEMENTS PERIOD ENDED SEPTEMBER 30, 2009    INDEX TO FINANCIAL STATEMENTS:PageConsolidated Balance Sheets
(Unaudited)4Consolidated Statements of Income (Unaudited)5-6Consolidated Statements of Cash Flows (Unaudited)7Consolidated Statements of Stockholders Equity (Unaudited)8Notes to Unaudited Financial Statements9-20    3


|                                                                                                                       |   |             |   |           
|---------------------------------------------------------------------------------------------------------------------- | - | ----------- | - | ----------
|SINOCOM PHARMACEUTICAL, INC.                                                                                          
|CONSOLIDATED BALANCE SHEETS                                                                                           
|AS OF SEPTEMBER 30, 2009 AND DECEMBER 31, 2008                                                                        
|                                                                                                                       |   |             |   |           
|ASSETS                                                                                                                 |   | 9/30/2009   |   | 12/31/2008
|                                                                                                                       |   | (Unaudited) |   | (Audited) 
|Current Assets                                                                                                         |   |             |   |           
|                                                                                                                       |   |             |   |           
|Cash and cash equivalents                                                                                              | $ | 21,174,269  | $ | 5,302,591 
|Accounts receivable, net                                                                                               |   | 16,032,934  |   | 11,912,091
|Inventory                                                                                                              |   | 1,875,672   |   | 2,798,019 
|Prepaid expenses and other receivables                                                                                 |   | 1,938,415   |   | 79,620    
|Total Current Assets                                                                                                   |   | 41,021,290  |   | 20,092,321
|                                                                                                                       |   |             |   |           
|Intangible assets, net                                                                                                 |   | 1,402,756   |   | -         
|Property & equipment, net                                                                                              |   | 625,922     |   | 691,630   
|Total Assets                                                                                                           | $ | 43,049,968  | $ | 20,783,951
|                                                                                                                       |   |             |   |           
|LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                   |   |             |   |           
|                                                                                                                       |   |             |   |           
|Current Liabilities                                                                                                    |   |             |   |           
|Accounts payable and accrued expenses                                                                                  | $ | 18,304,108  | $ | 6,715,190 
|Income tax payable                                                                                                     |   | 1,046,123   |   | 1,240,345 
|Due to related parties                                                                                                 |   | 290,103     |   | 163,212   
|Other payables                                                                                                         |   | 93,619      |   | 72,643    
|Total Current Liabilities                                                                                              |   | 19,733,953  |   | 8,191,390 
|                                                                                                                       |   |             |   |           
|Stockholders' Equity                                                                                                   |   |             |   |           
|                                                                                                                       |   |             |   |           
|Preferred stock, par value $.001; 20,000,000 shares authorized;                                                        |   |             |   |           
|no shares issued and outstanding                                                                                       |   | -           |   | -         
|Common stock, par value $.001; 150,000,000 shares authorized;  71,416,660 and 71,416,660 shares issued and outstanding |   | 71,417      |   | 71,417    
|Additional paid in capital                                                                                             |   | 323,463     |   | 323,463   
|Statutory reserve                                                                                                      |   | 7,617,885   |   | 7,617,885 
|Other comprehensive income                                                                                             |   | 4,896,207   |   | 4,884,220 
|Retained earnings                                                                                                      |   | 10,407,043  |   | (304,424) 
|Total Stockholders' Equity                                                                                             |   | 23,316,015  |   | 12,592,561
|Total Liabilities and Stockholders' Equity                                                                             | $ | 43,049,968  | $ | 20,783,951
|                                                                                                                       |   |             |   |           
|The accompanying notes are an integral part of these consolidated financial statements.                               

4


| |  |  |  | 
| |  |  |  | 




|                                                                                        |   |            |   |           
|--------------------------------------------------------------------------------------- | - | ---------- | - | ----------
|SINOCOM PHARMACEUTICAL, INC.                                                           
|CONSOLIDATED STATEMENTS OF INCOME                                                      
|FOR THE NINE MONTHS ENDED SEPTEMBER 30,                                                
|(UNAUDITED)                                                                            
|                                                                                        |   |            |   |           
|                                                                                        |   | 2009       |   | 2008      
|                                                                                        |   |            |   |           
|                                                                                        |   |            |   |           
|Sales, net                                                                              | $ | 56,081,037 | $ | 46,520,789
|                                                                                        |   |            |   |           
|Cost of sales                                                                           |   | 39,310,837 |   | 32,870,851
|Gross profit                                                                            |   | 16,770,200 |   | 13,649,938
|                                                                                        |   |            |   |           
|General and administrative expenses                                                     |   | 2,498,248  |   | 1,240,710 
|Income from operations                                                                  |   | 14,271,952 |   | 12,409,228
|                                                                                        |   |            |   |           
|Other (income) expense                                                                  |   |            |   |           
|Other expense                                                                           |   | 5,323      |   | 535       
|Interest expense                                                                        |   | -          |   | 175,518   
|Interest (income)                                                                       |   | (38,028)   |   | (257,881) 
|Total other (income) expense                                                            |   | (32,705)   |   | (81,828)  
|Income before income taxes                                                              |   | 14,304,657 |   | 12,491,056
|                                                                                        |   |            |   |           
|Provision for income taxes                                                              |   | 3,593,190  |   | 3,131,218 
|Net income                                                                              | $ | 10,711,467 | $ | 9,359,838 
|                                                                                        |   |            |   |           
|Net income per common share                                                             |   |            |   |           
|Basic and diluted                                                                       | $ | 0.15       | $ | 0.13      
|                                                                                        |   |            |   |           
|Weighted average common shares outstanding                                              |   |            |   |           
|Basic and diluted                                                                       |   | 71,416,660 |   | 70,988,327
|                                                                                        |   |            |   |           
|                                                                                        |   |            |   |           
|Consolidated Statements of Comprehensive Income                                         |   |            |   |           
|                                                                                        |   |            |   |           
|Net income                                                                              | $ | 10,711,467 | $ | 9,359,838 
|Foreign currency translation adjustment                                                 |   | 11,987     |   | 2,097,089 
|Comprehensive income                                                                    | $ | 10,723,454 | $ | 11,456,927
|                                                                                        |   |            |   |           
|The accompanying notes are an integral part of these consolidated financial statements.

5


|                                                                                        |   |            |   |           
|--------------------------------------------------------------------------------------- | - | ---------- | - | ----------
|SINOCOM PHARMACEUTICAL, INC.                                                           
|CONSOLIDATED STATEMENTS OF INCOME                                                      
|FOR THE THREE MONTHS ENDED SEPTEMBER 30,                                               
|(UNAUDITED)                                                                            
|                                                                                        |   |            |   |           
|                                                                                        |   | 2009       |   | 2008      
|                                                                                        |   |            |   |           
|Sales, net                                                                              | $ | 20,541,872 | $ | 13,682,264
|                                                                                        |   |            |   |           
|Cost of sales                                                                           |   | 15,051,987 |   | 9,839,501 
|Gross profit                                                                            |   | 5,489,885  |   | 3,842,763 
|                                                                                        |   |            |   |           
|General and administrative expenses                                                     |   | 940,677    |   | 558,293   
|Income from operations                                                                  |   | 4,549,208  |   | 3,284,470 
|                                                                                        |   |            |   |           
|Other (income) expense                                                                  |   |            |   |           
|Other expense                                                                           |   | 2,083      |   | 203       
|Interest expense                                                                        |   | -          |   | 75,874    
|Interest (income)                                                                       |   | (15,130)   |   | (188,534) 
|Total other (income) expense                                                            |   | (13,047)   |   | (112,457) 
|Income before income taxes                                                              |   | 4,562,255  |   | 3,396,927 
|                                                                                        |   |            |   |           
|Provision for income taxes                                                              |   | 1,041,475  |   | 832,775   
|Net income                                                                              | $ | 3,520,780  | $ | 2,564,152 
|                                                                                        |   |            |   |           
|Net income per common share                                                             |   |            |   |           
|Basic and diluted                                                                       | $ | 0.05       | $ | 0.04      
|                                                                                        |   |            |   |           
|Weighted average common shares outstanding                                              |   |            |   |           
|Basic and diluted                                                                       |   | 71,416,660 |   | 70,988,327
|                                                                                        |   |            |   |           
|                                                                                        |   |            |   |           
|Consolidated Statements of Comprehensive Income                                         |   |            |   |           
|                                                                                        |   |            |   |           
|Net income                                                                              | $ | 3,520,780  | $ | 2,464,518 
|Foreign currency translation adjustment                                                 |   | (12,391)   |   | (955,761) 
|Comprehensive income                                                                    | $ | 3,508,389  | $ | 1,508,757 
|                                                                                        |   |            |   |           
|                                                                                        |   |            |   |           
|The accompanying notes are an integral part of these consolidated financial statements.

6      SINOCOM PHARMACEUTICAL, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2009 AND 200820092008CASH FLOWS FROM OPERATING ACTIVITIESNet Income$10,711,467$9,359,838Adjustments to reconcile net income to net cashprovided by operating activities:Depreciation & Amortization115,62395,287Provision for bad debts--Loss on disposal of PP&E301-(Increase) / decrease in assets:Accounts receivables(4,110,226)6,848,747Inventory923,4843,839,024Prepaid expense and other receivables(1,859,529)10,519Increase / (decrease) in current liabilities:Accounts payable and accrued expenses11,762,886(7,330)Income tax payable(194,881)(2,284,910)Due to related parties147,615(1,252,737)Other payables(185,685)106,468Total Adjustments6,599,5887,355,068Net cash provided by operating activities17,311,05516,714,906CASH FLOWS FROM INVESTING ACTIVITIESPurchase of property & equipment(725)(198,977)Purchase of intangible assets(1,463,687)-Net cash used by investing activities(1,464,412)(198,977)CASH FLOWS FROM FINANCING ACTIVITIESProceeds from notes payable, net of repayments-1,266,469Net cash  provided by financing activities-1,266,469Effect of exchange rate changes on cash and cash equivalents25,0353,391,732Net change in cash and cash equivalents15,871,67821,174,130Cash and cash equivalents, beginning balance5,302,59139,535,132Cash and cash equivalents, ending balance$21,174,269$60,709,262SUPPLEMENTAL DISCLOSURES:Cash paid during the year for:Income tax payments$3,788,070$4,790,924Interest payments$-$175,518The accompanying notes are an integral part of these consolidated financial statements.   7


|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                            |   |           
|------------------------------------------------------------ | ------------------------------------------ | - | -------------------------- | - | -------------------------- | - | ----------------- | - | ----------------- | - | -------------------------- | - | ----------
|SINOCOM PHARMACEUTICAL, INC.                                
|CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
 (UNAUDITED)
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                           
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                           
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                           
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                           
|                                                             | Common Stock

Share                 Amount |   | Additional Paid-in-Capital |   | Other Comprehensive Income |   | Statutory Reserve |   | Retained Earnings |   | Total Stockholders Equity
|Balance December 31, 2007                                    | 71,416,660                                 | $ | 71,417                     | $ | 323,463                    | $ | 3,074,177         | $ | 7,617,885         | $ | 34,544,051                 | $ | 45,630,993
|Foreign currency translation adjustments                     |                                            |   |                            |   |                            |   | 2,097,089         |   |                   |   |                            |   | 2,097,089 
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                            |   |           
|Income for the nine months ended September 30, 2008          |                                            |   |                            |   |                            |   |                   |   |                   |   | 9,359,838                  |   | 9,359,838 
|Balance September 30, 2008                                   | 71,416,660                                 | $ | 71,417                     | $ | 323,463                    | $ | 5,171,266         | $ | 7,617,885         | $ | 43,903,889                 | $ | 57,087,920
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                           
|                                                             | Common Stock

Share                 Amount |   | Additional Paid-in-Capital |   | Other Comprehensive Income |   | Statutory Reserve |   | Retained Earnings |   | Total Stockholders Equity
|Balance December 31, 2008                                    | 71,416,660                                 | $ | 71,417                     | $ | 323,463                    | $ | 4,884,220         | $ | 7,617,885         | $ | (304,424)                  | $ | 12,592,561
|Foreign currency translation adjustments                     |                                            |   |                            |   |                            |   | 11,987            |   |                   |   |                            |   | 11,987    
|Income for the nine months ended September 30, 2009          |                                            |   |                            |   |                            |   |                   |   |                   |   | 10,711,467                 |   | 10,711,467
|Balance September 30, 2009                                   | 71,416,660                                 | $ | 71,417                     | $ | 323,463                    | $ | 4,896,207         | $ | 7,617,885         | $ | 10,407,043                 | $ | 23,316,015
|                                                             |                                            |   |                            |   |                            |   |                   |   |                   |   |                            |   |           

8   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   Note 1 - ORGANIZATION  Sinocom Pharmaceutical, Inc. (Sinocom or Company) was formed on September 13, 2007 in the State of Nevada.  The Company was originally incorporated as Tiger Acquisitions, Inc. and changed its name to Sinocom on February 26, 2009.  Through a Share Exchange, Rolling Rhine Holdings, Ltd and its wholly- owned subsidiaries, China Zhongxi Yao Group Ltd and Anqing Zhongxi Yao Ltd, became wholly-owned subsidiaries of the Company.  Rolling Rhine was incorporated in December 2007, under the laws of the British Virgin Islands as a holding company for the purposes of owning 100% of China Zhongxi Yao Group Ltd.  Rolling Rhine formed China Zhongxi Yao Group Limited, a Hong Kong company, for the purpose of owning 100% of the stock of Anqing Zhongxi Yao Ltd.  Anqing Zhongxi Yao Ltd, formed in December 1997, is organized under the laws of the Peoples Republic of China (PRC).  Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Basis of Presentation  The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company's functional currency is the Chinese Renminbi, however, the accompanying consolidated financial statements have been translated and presented in United States Dollars.  In 2008, Rolling Rhine and its wholly-owned subsidiary, China Zhongxi Yao Group Limited, entered into and consummated an agreement and plan of merger with Anqing Zhongxi Yao Ltd, a PRC corporation.  Rolling Rhine Holdings Limited was the surviving entity.  In substance, the agreement is a recapitalization of Anqing Zhongxi Yao Ltds capital structure.  On January 20, 2009, Sinocom entered into an Exchange Agreement with Rolling Rhine Holdings, Ltd  and its shareholders.  Upon the closing of the Share Exchange on February 20, 2009, the shareholders of Rolling Rhine delivered 300,000 shares of common stock of Rolling Rhine, representing all of its issued and outstanding common stock to Sinocom in exchange for 67,131,660 shares of common stock of Sinocom.  The Share Exchange is being accounted for as a reverse merger since the stockholders of Rolling Rhine own a majority of the outstanding shares of Sinocoms common stock immediately following the Share Exchange.  Under accounting principles generally accepted in the United States, the share exchange is considered to be a capital transaction in substance, rather than a business combination. Thus the share exchange is equivalent to the issuance of stock by Rolling Rhine for the net monetary assets of Sinocom, accompanied by a recapitalization, and is accounted for as a change in capital structure. Accordingly, the accounting for the share exchange was identical to that resulting from a reverse acquisition, except no goodwill was recorded. Under reverse takeover accounting, the post reverse acquisition comparative historical financial statements of the legal acquirer, Sinocom, are those of the legal acquiree, Rolling Rhine, which is considered to be the accounting acquirer, and thus represent a continuation of the financial statements of Rolling Rhine. Share and per share amounts stated have been retroactively adjusted to reflect the merger.  The accompanying financial statements present the historical financial condition, results of operations and cash flows of the operating company prior to the recapitalization.      9   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   Translation Adjustment  As of September 30, 2009 and December 31, 2008, the accounts of the Company were maintained, and its financial statements were expressed, in Chinese Yuan Renminbi (CNY). Such financial statements were translated into U.S. Dollars (USD) in accordance with the Foreign Currency Matters Topic of the FASB Accounting Standards Codification (ASC 830), with the CNY as the functional currency. According to ASC 830, all assets and liabilities were translated at the current exchange rate, stockholders equity are translated at the historical rates and income statement items are translated at the average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with the Comprehensive Income Topic of the FASB Accounting Standards Codification (ASC 220), as a component of shareholders equity.  Transaction gains and losses are reflected in the income statement.  Use of Estimates  The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  Risks and Uncertainties  The Companys operations are carried out in the PRC.  Accordingly, the Companys business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, by the general state of the PRCs economy.  The Companys business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.  The Company is subject to substantial risks from, among other things, intense competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, foreign currency exchange rates and the volatility of public markets.  Contingencies  Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Companys management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Companys legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.  If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Companys financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.    10   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.  Cash and Cash Equivalents  Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.  Accounts Receivable  The Company maintains reserves for potential credit losses on accounts receivable.   Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves.  Reserves are recorded primarily on a specific identification basis.  There were no allowances for doubtful accounts as of September 30, 2009 and December 31, 2008, respectively.  Inventories  Inventories are valued at the lower of cost (determined on a weighted average basis) or market. The Management compares the cost of inventories with the market value and allowance is made for writing down their inventories to market value, if lower. As of September 30, 2009 and December 31, 2008 inventory consisted of finished goods valued at $1,875,672 and $2,798,019, respectively.  Property, Plant & Equipment  Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of:  Buildings20 yearsTransportation equipment5 yearsElectronics5 years   At September 30, 2009 and December 31, 2008, Property, Plant & Equipment consist of the following:  20092008Buildings$809,494$209,494Transportation equipment191,101197,123Electronics87,57386,847Total1,088,1681,093,464Accumulated depreciation(462,246)(401,834)$625,922$691,630    11   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   Intangible Assets  Intangible assets are amortized using the straight-line method over their estimated period of benefit. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No impairments of intangible assets have been identified during any of the periods presented. The land rights purchased in 2009 will expire in 2019. All of the Companys intangible assets are subject to amortization with estimated lives of:  Land use right10 years  As of September 30, 2009 and December 31, 2008, the components of finite-lived intangible assets are as follows:  09/30/200912/31/2008Land use right$1,463,687$-Less: Accumulated amortization(60,931)-$1,402,756$-  Amortized expense for September 30, 2009 and December 31, 2008 was $60,931 and $-0- respectively.  The estimated future amortization expenses related to intangible asset as of September 30, 2009 are as follows:  Years Ending September 30,2010$146,1442011146,1442012146,1442013146,1442014146,144Thereafter672,036  Long-Lived Assets  Effective January 1, 2002, the Company adopted the Property, Plant, and Equipment Topic of the FASB Accounting Standards Codification (ASC 360), which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of, and the accounting and reporting provisions of Accounting Principles Board Opinion No. 30, Reporting the Results of Operations for a Disposal of a Segment of a Business. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. Based on its review, the Company believes that, as of September 30, 2009, there were no significant impairments of its long-lived assets.   12   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009    Fair Value of Financial Instruments  The Financial Instrument Topic of the FASB Accounting Standards Codiciation (ASC 825 requires that the Company disclose estimated fair values of financial instruments. The carrying amounts reported in the statements of financial position for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.  Revenue Recognition  The Companys revenue recognition policies are in compliance with the Revenue Recoginition Topic of the FASB Accounting Standards Codification (ASC 605). Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectibility is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.  Stock-Based Compensation  The company accounted for stock-based compensation in accordance with SFAS No. 123(R), Share-Based Payment. Under the fair value recognition provisions of this statement, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period. Determining the fair value of stock-based awards at the grant date requires judgment, including estimating expected dividends. In addition, judgment is also required in estimating the amount of stock-based awards that are expected to be forfeited. If actual results differ significantly from these estimates, stock-based compensation expense and our results of operations could be impacted. SFAS No. 123(R) was superseded by the Compensation  Stock Compensation Topic of the FASB Accounting Standards Codification (ASC 718).  Advertising Advertising expenses consist primarily of costs of promotion for corporate image and product marketing and costs of direct advertising. The Company expenses all advertising costs as incurred.  Advertising costs were $15 and $336 for the nine months ended September 30, 2009 and 2008, respectively.  Income Taxes  The Statement of Financial Accounting Standards, No. 109, Income Taxes requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred taxes to the amount expected to be realized.    13   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   In July 2006, the FASB released FASB interpretation No. 48, Accounting for Uncertainty in Income Taxes, an interpretation of SFAS No. 109, (FIN No. 48).  FIN No. 48 clarifies the accounting and reporting for uncertainties in income tax law.  This interpretation prescribes a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.  This Statement is effective for fiscal years beginning after December 15, 2006. As a result of implementing FIN No. 48, there have been no adjustments to the Companys financial statements. SFAS No. 109 and FIN No 48 were superseded by the Income Taxes Topic of the FASB Accounting Standards Codification (ASC 740) in September 2009.  Basic and Diluted Earnings per Share  Earnings per share are calculated in accordance with the Earnings Per Share Topic of the FASB Accounting Standards Codification (ASC  260). Net loss per share for all periods presented has been restated to reflect the adoption of ASC 260. Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.  Statement of Cash Flows  In accordance with the Statement of Cash Flows Topic of the FASB Accounting Standards Codification (ASC 230), cash flows from the Companys operations are based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.  Concentration of Credit Risk  Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base, most of which are in China. The Company controls credit risk related to accounts receivable through credit approvals, credit limits and monitoring procedures. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.  Recent Accounting Pronouncements  The Derivatives and Hedging Topic of the FASB Accounting Standards, Codification (ASC 815) permits fair value re-measurement for any hybrid financial instrument that contains an embedded derivative that otherwise would require bifurcation, clarifies which interest-only strips and principal-only strips are not subject to the requirements of SFAS No. 133, establishes a requirement to evaluate interest in securitized financial assets to identify interests that are freestanding derivatives or that are hybrid financial instruments that contain an embedded derivative requiring bifurcation, clarifies that concentrations of credit risk in the form of subordination are not embedded derivatives, and amends SFAS No. 140 to eliminate the prohibition on the qualifying special-purpose entity from holding a derivative financial instrument that pertains to a beneficial   14   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   interest other than another derivative financial instrument. This statement is effective for all financial instruments acquired or issued after the beginning of the Companys first fiscal year that begins after September 15, 2006.  In March 2006, the FASB issued SFAS No. 156, Accounting for Servicing of Financial Assets  an amendment to FASB Statement No. 140. SFAS No. 156 requires that an entity recognize a servicing asset or servicing liability each time it undertakes an obligation to service a financial asset by entering into a service contract under certain situations. The new standard is effective for fiscal years beginning after September 15, 2006. SFAS No. 156 was superseded by the Transfer and Servicing Topic of the FASB Accounting Standards Codification (ASC 860). The adoption of this new standard did not have a material impact on the Companys financial position, results of operations or cash flows.  In September, 2006, FASB issued SFAS No. 157, Fair Value Measurements.  This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements.  This Statement applies under other accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute.  Accordingly, this Statement does not require any new fair value measurements.  However, for some entities, the application of this Statement will change current practice.  This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.  SFAS No. 157 was superseded by the Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification (ASC 820). The adoption of this Statement had no material impact on the Companys results.  In September 2006, FASB issued SFAS No. 158, Employers Accounting for Defined Benefit Pension and Other Postretirement Plans  an amendment of FASB Statements No. 87, 88, 106, and 132(R) (SFAS No. 158). SFAS No. 158 improves financial reporting by requiring an employer to recognize the over funded or under funded status of a defined benefit postretirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position and to recognize changes in that funded statues in the year in which the changes occur through comprehensive income of a business entity or changes in unrestricted net assets of a not-for-profit organization.  This Statement also improves financial reporting by requiring an employer to measure the funded status of a plan as of the date of its year-end statement of financial position, with limited exceptions. An employer with publicly traded equity securities is required to initially recognize the funded status of a defined benefit postretirement plan and to provide the required disclosures as of the end of the fiscal year ending after December 15, 2006.  An employer without publicly traded equity securities is required to recognize the funded status of a defined benefit postretirement plan and to provide the required disclosures as of the end of the fiscal year ending after June 15, 2007.  However, an employer without publicly traded equity securities is required to disclose the following information in the notes to financial statements for a fiscal year ending after December 15, 2006, but before June 16, 2007, unless it has applied the recognition provisions of this Statement in preparing those financial statements.  a. A brief description of the provisions of this Statement b. The date that adoption is required c. The date the employer plans to adopt the recognition provisions of this Statement, if earlier.  The requirement to measure plan assets and benefit obligations as of the date of the employers fiscal year-end statement of financial position is effective for fiscal years ending after December 15, 2008. SFAS No. 158 was superseded by the Compensation  Retirement Benefits Topic of the FASB Accounting Standards Codification (ASC 715). The Company believes that the adoption of these standards will have no material impact on its   15   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   financial statements.  In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (SAB 108).  SAB 108 was issued to provide interpretive guidance on how the effects of the carryover reversal of prior year misstatements should be considered in quantifying a current year misstatement. The provisions of SAB 108 are effective for the Company for its December 31, 2006 year-end.  The adoption of SAB 108 had no impact on the Companys consolidated financial statements.  In February, 2007, FASB issued SFAS 159, The Fair Value Option for Financial Assets and Financial Liabilities  Including an Amendment of FASB Statement No. 115.  This Statement permits entities to choose to measure many financial instruments and certain other items at fair value. This Statement is expected to expand the use of fair value measurement, which is consistent with the Boards long-term measurement objectives for accounting for financial instruments.  This Statement is effective as of the beginning of an entitys first fiscal year that begins after November 15, 2007. SFAS No. 159 was superseded by the Financial Instruments Topic of the FASB Accounting Standards Codification (ASC 825). The adoption of this Statement had no impact on the Companys consolidated financial statements.  In December 2007, the FASB issued SFAS No. 160, Non-Controlling Interests in Consolidated Financial Statements.  This Statement amends ARB 51 to establish accounting and reporting standards for the non-controlling (minority) interest in a subsidiary and for the deconsolidation of a subsidiary.  It clarifies that a non-controlling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements.  SFAS No. 160 is effective for the Companys fiscal year beginning October 1, 2009. SFAS No. 160 was superseded by the Consolidation Topic of the FASB Accounting Standards Codification (ASC 810). Management is currently evaluating the effect of this pronouncement on financial statements.  In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities.  The new standard is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entitys financial position, financial performance, and cash flows.  It is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged.  The new standard also improves transparency about the location and amounts of derivative instruments in an entitys financial statements; how derivative instruments and related hedged items are accounted for under Statement 133: and how derivative instruments and related hedged items affect its financial position, financial performance, and cash flows.  SFAS No. 161 was superseded by the Derivative and Hedging Topic of the FASB Accounting Standards Codification (ASC 815). Management is currently evaluating the effect of this pronouncement on financial statements.  In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting Principles.  This Statement will provide a framework for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP) for nongovernmental entities.  With the issuance of SFAS No. 162, the GAAP hierarchy for nongovernmental entities will move from auditing literature to accounting literature. SFAS No. 162 was superseded by the Generally Accepted Accounting Principles Topic of the FASB Accounting Standards Codification (ASC 105). The Company is currently assessing the impact of SFAS No. 162 on its financial position and results of operations.  In June 2008, the FASB ratified EITF No. 07-5, Determining Whether an Instrument (or Embedded Feature)   16   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   Is Indexed to an Entitys Own Stock (EITF No. 07-5). EITF No. 07-5 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instruments contingent exercise and settlement provisions. It also clarifies the impact of foreign currency denominated strike prices and market-based employee stock option valuation instruments on the evaluation. EITF No. 07-5 is effective for fiscal years beginning after December 15, 2008. We adopted EITF No. 07-5 effective January 1, 2009. EITF No. 07-5 was superseded by the Derivatives and Hedging Topic of the FASB Accounting Standards Codification (ASC 815). The adoption of ASC 815 has no impact on our financial statements.  In April 2009, the Financial Accounting Standards Board (FASB) issued the following new accounting standards:   ·FASB Staff Position FAS No. 157-4, Determining Whether a Market Is Not Active and a Transaction Is Not Distressed,(“FSP FAS No. 157-4”) provides guidelines for making fair value measurements more consistent with the principles presented in SFAS No. 157.  FSP FAS No. 157-4 provides additional authoritative guidance in determining whether a market is active or inactive and whether a transaction is distressed. It is applicable to all assets and liabilities (i.e., financial and non-financial) and will require enhanced disclosures. FSP FAS No. 157-4 was superseded by the Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification (ASC 820).  ·FASB Staff Positions FAS No. 115-2, FAS 124-2, and EITF No. 99-20-2, Recognition and Presentation of Other-Than-Temporary Impairments, (“FSP FAS No. 115-2, FAS No. 124-2, and EITF No. 99-20-2”) provides additional guidance to provide greater clarity about the credit and noncredit component of an other-than-temporary impairment event and to more effectively communicate when an other-than-temporary impairment event has occurred. This FSP applies to debt securities. FSP FAS No. 115-2 and FAS No. 124-2 were superseded by the Investments-Debt and Equity Securities Topic of the FASB Accounting Standards Codification (ASC 320).  ·FASB Staff Position FAS No. 107-1 and APB No. 28-1, Interim Disclosures about Fair Value of Financial Instruments, (“FSP FAS No. 107-1 and APB No. 28-1”) amends FASB Statement No. 107, Disclosures about Fair Value of Financial Instruments, to require disclosures about fair value of financial instruments in interim as well as in annual financial statements. This FSP also amends APB Opinion No. 28, Interim Financial Reporting, to require those disclosures in all interim financial statements. FSP FAS No. 107-1 and APB No. 28-1were superseded by the Financial Instruments Topic of the FASB Accounting Standards Codification (ASC 825).  These standards are effective for periods ending after June 15, 2009. We are evaluating the impact that these standards will have on our consolidated financial statements.  On July 1, 2009, the Company adopted Accounting Standards Update (ASU) No. 2009-01, Topic 105 - Generally Accepted Accounting Principles - amendments based on Statement of Financial Accounting Standards No. 168 - The FASB Accounting Standards CodificationTM and the Hierarchy of Generally Accepted Accounting Principles (ASU No. 2009-01).  ASU No. 2009-01 re-defines authoritative GAAP for nongovernmental entities to be only comprised of the FASB Accounting Standards CodificationTM (Codification) and, for SEC registrants, guidance issued by the SEC.  The Codification is a reorganization and compilation of all then-existing authoritative GAAP for nongovernmental entities, except for guidance issued by the SEC.  The Codification is amended to effect non-SEC changes to authoritative GAAP.  Adoption   17   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009   of ASU No. 2009-01 only changed the referencing convention of GAAP in Notes to the Condensed Consolidated Financial Statements.  Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not, or are not believed by management to, have a material impact on the Companys present or future consolidated financial statements.  Note 3  DUE TO RELATED PARTIES  The Company has payables due to several related parties.  As of September 30, 2009 and December 31, 2008, due to related parties were $290,103 and $163,212, respectively.  Note 4  COMPENSATED ABSENCES  Regulation 45 of the local labor law of the Peoples Republic of China (PRC) entitles employees to annual vacation leave after 1 year of service.  In general, all leave must be utilized annually, with proper notification.  Any unutilized leave is cancelled.  Note 5 - INCOME TAXES  Pursuant to the PRC Income Tax Laws, the Enterprise Income Tax (EIT) through December 31, 2007 is at a statutory rate of 33%, which is comprised of 30% national income tax and 3% local income tax.  As of January 1, 2008, the EIT is at a statutory rate of 25%.  The following is a reconciliation of income tax expense for the nine months ended September 30, 2009 and 2008:  9/30/2009U.S.InternationalTotalCurrent$-$3,593,190$3,593,190Deferred--Total$-$3,593,190$3,593,1909/30/2008U.S.InternationalTotalCurrent$-$3,131,218$3,131,218Deferred--Total$-$3,131,218S3,131,218
  Due to the uncertainty surrounding the realization of the favorable U.S. tax attributes in future tax returns, we continue to record a full valuation allowance against our otherwise recognizable U.S. net deferred tax assets as of September 30, 2009 and December 31, 2008.  Note 6  COMMITMENTS & CONTINGENCIES  The Company leases facilities under operating leases, extending through January 2018 that it pays for on an annual basis and accrues for throughout the year.   For the nine months ended September 30, 2009 and 2008, rent expense was $320,132 and $241,129, respectively.  The future minimum obligations under these agreements are as follows:   18   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009    Year 1 $   345,879 Year 2 $   345,879 Year 3 $   345,879 Year 4 $   345,879 Year 5 $   344,083 Thereafter $   909,982  The Company has entered into a land lease for 50 years through April 30, 2059. Terms of lease call for 5 payments at the beginning of each ten year period.  The future minimum obligation under the lease total $5,856,515 with second payment due May 1, 2019. Any breach by either party to the lease calls for a penalty payment of approximately $146,000 plus any economic loss incurred. The first payment has been capitalized and is being amortized over ten years. Amortization expense for the nine months ended September 30, 2009 and 2008 totaled $60,931 and $0, respectively.  Note 7  STATUTORY RESERVE  In accordance with the laws and regulations of the PRC, a wholly-owned Foreign Invested Enterprises income, after the payment of the PRC income taxes, shall be allocated to the statutory surplus reserves and statutory public welfare fund. Prior to January 1, 2006 the proportion of allocation for reserve was 10 percent of the profit after tax to the surplus reserve fund and additional 5-10 percent to the public affair fund. The public welfare fund reserve was limited to 50 percent of the registered capital.  Effective January 1, 2006, there is now only one fund requirement. The reserve is 10 percent of income after tax, not to exceed 50 percent of registered capital.  Statutory Reserve funds are restricted for set off against losses, expansion of production and operation or increase in register capital of the respective company. Statutory public welfare fund is restricted to the capital expenditures for the collective welfare of employees. These reserves are not transferable to the Company in the form of cash dividends, loans or advances. These reserves are therefore not available for distribution except in liquidation. As of September 30, 2009 and December 31, 2008, the Company had allocated $7,617,885 and $7,617,885, respectively, to these non-distributable reserve funds.   Note 8 - OTHER COMPREHENSIVE INCOME  Balances of related after-tax components comprising accumulated other comprehensive income, included in stockholders equity, at September 30, 2009 and 2008, are as follows:  Nine Months Ended September 30, 20092008Balance at December 31, 2008 and 2007$4,884,220$3,076,412Foreign currency translation adjustment11,9872,097,089Balance at 09/30/2009 and 09/30/2008$4,896,207$5,173,501
  The components of accumulated other comprehensive income, net of related taxes at September 30, 2009 and December 31, 2008 are as follows.    19   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2009    September 30, 2009December 31, 2008Foreign currency translation adjustment$4,896,207$4,884,220
  Note 9 - CURRENT VULNERABILITY DUE TO CERTAIN RISK FACTORS  The Companys operations are carried out in the PRC. Accordingly, the Companys business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, by the general state of the PRC's economy. The Companys business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.  Note 10  MAJOR CUSTOMERS AND CREDIT RISK  No customer accounted for more than 10% of accounts receivable at September 30, 2009 or December 31, 2008.  No customer accounted for greater than 10% of sales for the nine months ending September 30, 2009 and 2008.  No vendor accounted for more than 10% for the nine months ended September 30, 2009 and the top two vendors accounted for 38.93% of purchases for the nine months ended September 30, 2008. At September 30, 2009 and December 31, 2008, no vendor accounted for more than 10% of accounts payable.   Note 10  SUBSEQUENT EVENT  On October 28, 2009, the Company entered into a Series A Preferred Stock Purchase Agreement (the Agreement) with key shareholders and some investors. Subject to the conditions set forth therein the Agreement, the Company will authorize and issue and the Investors will agree to purchase up to $15,000,000 of the Companys convertible, redeemable Series A Preferred Stock, $0.001 par value per share (the Series A Preferred Stock) that it intends to authorize immediately prior to the closing, at a price of $0.9465 per share of Series A Preferred Stock. Under the terms of the Purchase Agreement and subject to the conditions set forth therein, the shares of Series A Preferred Stock to be issued on the closing of the transactions contemplated by the Purchase Agreement shall initially be convertible into shares of the Companys common stock, par value $0.001 per share (the Common Stock) constituting 18.16% of the outstanding shares of Common Stock of the Company, determined on a fully-diluted basis.   20     ITEM 2. MANAGEMENTS DISCUSSIONS AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.  SPECIAL NOTE OF CAUTION REGARDING FORWARD-LOOKING STATEMENTS  CERTAIN STATEMENTS IN THIS REPORT, INCLUDING STATEMENTS IN THE FOLLOWING DISCUSSION, ARE WHAT ARE KNOWN AS "FORWARD LOOKING STATEMENTS", WHICH ARE BASICALLY STATEMENTS ABOUT THE FUTURE. FOR THAT REASON, THESE STATEMENTS INVOLVE RISK AND UNCERTAINTY SINCE NO ONE CAN ACCURATELY PREDICT THE FUTURE. WORDS SUCH AS "PLANS," "INTENDS," "WILL," "HOPES," "SEEKS," "ANTICIPATES," "EXPECTS "AND THE LIKE OFTEN IDENTIFY SUCH FORWARD LOOKING STATEMENTS, BUT ARE NOT THE ONLY INDICATION THAT A STATEMENT IS A FORWARD LOOKING STATEMENT. SUCH FORWARD LOOKING STATEMENTS INCLUDE STATEMENTS CONCERNING OUR PLANS AND OBJECTIVES WITH RESPECT TO THE PRESENT AND FUTURE OPERATIONS OF THE COMPANY, AND STATEMENTS WHICH EXPRESS OR IMPLY THAT SUCH PRESENT AND FUTURE OPERATIONS WILL OR MAY PRODUCE REVENUES, INCOME OR PROFITS. NUMEROUS FACTORS AND FUTURE EVENTS COULD CAUSE THE COMPANY TO CHANGE SUCH PLANS AND OBJECTIVES OR FAIL TO SUCCESSFULLY IMPLEMENT SUCH PLANS OR ACHIEVE SUCH OBJECTIVES, OR CAUSE SUCH PRESENT AND FUTURE OPERATIONS TO FAIL TO PRODUCE REVENUES, INCOME OR PROFITS. THEREFORE, THE READER IS ADVISED THAT THE FOLLOWING DISCUSSION SHOULD BE CONSIDERED IN LIGHT OF THE DISCUSSION OF RISKS AND OTHER FACTORS CONTAINED IN THIS REPORT ON FORM 10-Q AND IN THE COMPANY'S OTHER FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. NO STATEMENTS CONTAINED IN THE FOLLOWING DISCUSSION SHOULD BE CONSTRUED AS A GUARANTEE OR ASSURANCE OF FUTURE PERFORMANCE OR FUTURE RESULTS.  Company Overview The Registrant was incorporated in the state of Nevada on September 13, 2007, as Tiger Acquisitions, Inc. As disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 20, 2009, as amended in Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 23, 2009, on February 20, 2009, pursuant to the terms of a Share Exchange Agreement, the Registrant acquired Rolling Rhine Holdings, Ltd., a corporation organized under the laws of the British Virgin Islands (Rolling Rhine), and its wholly-owned subsidiaries, China Zhongxi Yao Group Limited, a Hong Kong corporation (China Zhongxi), and Anqing Zhongxi Yao, Ltd., a PRC corporation (Anqing Zhongxi).  Through the closing of the share exchange transaction, the Registrant succeeded to the business carried on by Anqing Zhongxi as its sole line of business.  This transaction was accounted for as a reverse merger with Rolling Rhine deemed to be the accounting acquirer and the Registrant as the legal acquirer.  Consequently, the assets and liabilities and the historical operations that will be reflected in the financial statements for periods prior to the Share Exchange will be those of Rolling Rhines operating subsidiary, Anqing Zhongxi, recorded at the historical cost basis of Anqing Zhongxi.  After completion of the Share Exchange, the Registrants consolidated financial statements will include the assets and liabilities of both the Registrant and Anqing Zhongxi, the historical operations of Anqing Zhongxi and the operations of the Registrant and its subsidiaries from the closing date of the Share Exchange.  Anqing Zhongxi is a leading PRC pharmaceutical company which grows and sells natural herbs and which sells a wide variety of third party TCM (Traditional Chinese Medicine) formulated products and western medicines. The pharmaceutical products, which include both over-the-counter and prescription products, are sold in direct channels to hospitals, medical clinics and drug stores, as well as in indirect channels to other   21     distributors. The herbs are sold in unprocessed form and are sold to customers in bulk.  None of the sales of pharmaceutical products or herbs are made directly to retail customers.  Anqing Zhongxi is based in Anqing City, Anhui Province, PRC  Results of Operation  The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our results of operation and financial condition for the three and nine month periods ended September 30, 2009 and 2008.  Our financial statements are stated in US Dollars and are prepared in accordance with generally accepted accounting principals of the United States (GAAP).  Results of Operation for Sinocom Pharmaceutical, Inc., for the Three and Nine Months Ended September 30, 2009 Compared to the Three and Nine Months Ended September 30, 2008.  Sales


|                      |                    |                   |            |             |             |            
|--------------------- | ------------------ | ----------------- | ---------- | ----------- | ----------- | -----------
|                      | Three months ended | Nine months ended
|Sep 30,               | Sep 30,           
|                      | 2009               | 2008              | Increase / | 2009        | 2008        | Increase / 
|(Decrease)            | (Decrease)        
|$ Change              | $ Change          
|Distribution          | $20,159,068        | $13,682,264       | $6,476,804 | $48,213,570 | $32,331,218 | $15,882,352
|Natural Herbs         | 382,805            | -                 | 382,805    | 7,867,467   | 795,962     | 7,071,506  
|Discontinued Products |                    |                   |            |             | 13,393,609  | -13,357,656
|Total sales           | $20,541,872        | $13,682,264       | $6,859,608 | $56,081,037 | $46,520,789 | $9,596,201 

The increase in revenue for the three and nine month periods ended September 30, 2009, as compared to the same period in 2008, was due to the higher sales achieved in third party formulated products and natural herbs thus offsetting the impact from the discontinued products in Q2 2008.  Cost of Sales  Cost of sales was $15,051,987 and $9,839,501, for the three months ended September 30, 2009 and 2008, respectively and $39,310,832 and $32,970,851, for the nine months ended September 30, 2009 and 2008, respectively. The increase was primarily attributable to higher sales volume for the same period.  Gross Profit  Gross profit for the three months ended September 30, 2009, increased $1,647,122 to $5,489,885 from $3,842,763 primarily as a result of higher sales volume. Gross profit for nine months ended September 30, 2009, increased 22.9% to $16,770,200 from $13,649,938 for nine months ended September 30, 2008 due to the increased sales volume for the same period.  General and Administrative Expenses  For the three months ended September 30, 2009, general and administrative expenses were $940,677 as   22     compared to general and administrative expenses of $558,293 for the three months ended September 30, 2008. General and administrative expenses were $2,498,248 and $1,240,710 for the nine months ended September 30, 2009 and 2008, respectively. The increase was primarily attributable to increased plantation land rental charges and sales promotional expenses recognized in current year. In 2008, the sales promotional expenses were recognized only in December 2008.  Net Income  The Company recorded net income of $3,520,780 and $2,564,152 for the three months ended September 30, 2009 and 2008, respectively. The Company recorded net income of $10,711,467 and $9,359,838 for the nine months ended September 30, 2009 and 2008, respectively.  Liquidity and Capital Resources We anticipate that the existing cash and cash equivalents on hand, together with the net cash flows generated from our business activities will be sufficient to meet our working capital requirements for our current level of operations and to sustain our business operations at the current levels for the next twelve months.  Subsequent Event  As reported in a Current Report on Form 8-K dated October 28, 2009, and filed with the Securities and Exchange Commission on October 30, 2009, on October 28, 2009, on October 28, 2009, the Company entered into a Series A Preferred Stock Purchase Agreement (the Agreement) with key shareholders and some Investors. Subject to the conditions set forth in the Agreement, the Company will authorize and issue and the Investors will purchase up to $15,000,000 of the Companys convertible, redeemable Series A Preferred Stock, $0.001 par value per share (the Series A Preferred Stock) that it intends to authorize immediately prior to the closing, at a price of $0.9465 per share of Series A Preferred Stock.  In the event the conditions set forth in the Agreement are satisfied and the Company completes the sale of up to of its Series A Preferred Stock pursuant to the terms of the Agreement, of which there can be no assurance, the Company will use approximately $9,000,000 of the net proceeds for construction of a modern distribution center and will use the balance for acquisition of land and construction of a research and development facility for its herbs business and for working capital.  Total Current Assets & Total Assets  As of September 30, 2009, we had current and total assets of $41,021,290 and $43,049,968, respectively, as compared to current and total assets of $20,092,321 and $20,783,951, respectively, as of December 31, 2008.  The increase in current assets and total assets from December 31, 2008 to September 30, 2009, of $20,928,969 and $22,266,017, respectively, are primarily attributable to higher cash and accounts receivables.  Total Current Liabilities  As of September 30, 2009, we had total current liabilities of $19,733,953, as compared to total current liabilities of $8,191,390, as of December 31, 2008.  The increase in total current liabilities of $11,542,563 is primarily attributable to higher trade payables.  Cash Flow for September 30, 2009 as Compared to December 31, 2008  Operating Activities.  Net cash provided by operating activities was $17,311,055 for the nine months ended September 30, 2009, as   23     compared to $16,714,906 for the nine months ended September 30, 2008. The increase of $596,149 was attributable to increased accounts payables and accrued expenses as at September 30, 2009.  Investing Activities  Net cash used by investing activities was $1,464,412 for the nine months ended September 30, 2009, as compared to $198,977 for the six months ended June 30, 2008. The increase of $1,265,435 was attributable to land rights acquired as at September 30, 2009.  Financing Activities  There was no cash used by financing activities for the nine months ended September 30, 2009 as compared to $1,266,469 for the nine months ended September 30, 2008.    Off Balance Sheet Arrangements  As of September 30, 2009 Company does not have any off balance sheet arrangements.  ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.  Not Applicable  ITEM 4T. CONTROLS AND PROCEDURES.  Disclosure Controls and Procedures  The Securities and Exchange Commission defines the term disclosure controls and procedures to mean the   controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuers management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.  The Company maintains such a system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC's rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.  As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures.  Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are designed to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized and reported within the time periods specified.  Our chief executive officer and chief financial officer also   24     concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.  Changes in Internal Control over Financial Reporting  There was no change in the Company's internal control over financial reporting during the period ended September 30, 2009, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.  PART II-OTHER INFORMATION  ITEM 1. LEGAL PROCEEDINGS.  The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.  ITEM 1A. RISK FACTORS.  Not Applicable.  ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.  Not Applicable     ITEM 3. DEFAULTS UPON SENIOR SECURITIES.  None.  ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.  None.  ITEM 5. OTHER INFORMATION.  None.  ITEM 6. EXHIBITS.  (a) The following exhibits are filed herewith:  31.1 Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*  31.2 Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*    25     32.1 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*  32.2 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*  * filed herewith  SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  SINOCOM PHARMACEUTICAL, INC.   By: /s/ XueXiang Ai, Chief Executive Officer  Date:  November 12, 2009   By:     /s/ Tuck Wing Pang, Chief Financial Officer  Date:  November 12, 2009   26